CQN-MA-RENAGADE
29.4.2024 23:01:34 CEST | Business Wire | Press release
Please replace the release dated April 26, 2024 with the following corrected version due to multiple revisions.
The updated release reads:
RENAGADE THERAPEUTICS CONTINUES COMMITMENT TO GANNA BIO AND GLYCAN BIOLOGY
GanNA founders include Carolyn Bertozzi, Ph.D., Richard D. Cummings, Ph.D., Ryan A. Flynn, M.D., Ph.D., and Namita Bisaria, Ph.D., M.B.A.
Additional investment strengthens ReNAgade’s delivery platform with unique conjugation platform based on novel glycobiology
ReNAgade Therapeutics, a company unlocking the limitless potential for RNA medicines, today announced its ongoing commitment to unlock the potential of glycobiology through support for ongoing research at GanNA Bio, and an integration of the key founders of GanNA Bio into the ReNAgade ecosystem.
GanNA Bio was formed in 2021 and invested in by ReNAgade to harness novel glycobiology to enable extra-hepatic RNA delivery based on pioneering research licensed from Stanford University, Boston Children’s Hospital, and Beth Israel Deaconess Medical Center, which was developed in the labs of Carolyn Bertozzi, Ph.D., winner of the 2022 Nobel Prize in Chemistry and Professor of Chemistry in the Stanford School of Humanities and Sciences; Ryan A. Flynn, M.D., Ph.D., Assistant Professor at Boston Children’s Hospital; and Richard D. Cummings, Ph.D., S. Daniel Abraham Professor of Surgery at Beth Israel Deaconess Medical Center, and led by Namita Bisaria, Ph.D., M.B.A., a serial entrepreneur in the RNA therapeutics field. Its platform, based on new advances in glycobiology and synthesis, uses cell-specific glycans to develop next-generation conjugates and to unlock the delivery of short and long stranded RNA medicines.
“ReNAgade will continue to benefit tremendously from GanNA’s promising work in developing extra-hepatic delivery technology that helps expand the breadth and potential of our own RNA medicines,” said Brian Goodman, Co-founder of ReNAgade. “Delivery is foundational to ReNAgade’s mission to overcome the current limitations of RNA medicines. We believe the technology developed within GanNA will help further solidify ReNAgade’s leadership position as we continue advancing our unique, integrated therapeutic platform.” GanNA founders Bertozzi and Cummings will now serve as advisors to ReNAgade.
“The progress in glycoRNA science from our seminal publication in the journal Cell is moving fast, and integration with ReNAgade’s pipeline will strengthen our position to develop a broad portfolio of cell specific delivery systems, leveraging the latest developments in glycobiology in order to expand the array of addressable diseases of RNA medicines,” said Ryan Flynn.
Dr. Bertozzi added, “The combination of GanNA’s innovative glycobiology-based targeting strategy with ReNAgade’s experience in the development of RNA medicines will be a powerful combination for the benefit of patients.” Dr. Cummings noted that “Glycobiology-based RNA medicines represent a new frontier, and it is rewarding to see the possibilities of ReNAgade developing these for clinical use.”
About ReNAgade Therapeutics
ReNAgade exists to unlock the potential for RNA medicines to treat disease anywhere in the body. We combine our novel RNA delivery platforms with a comprehensive RNA platform allowing for an all-RNA system for coding, editing, and gene insertion to develop new medicines.
To accelerate the future of medicine, we bring together a team with deep RNA and delivery expertise to develop paradigm-shifting RNA medicines.
ReNAgade Therapeutics—RNA Without Limits
For more information about the company, its technologies, and its leadership, visit www.renagadetx.com
About GanNA Bio
GanNA was created by Drs. Flynn and Bisaria, and invested by ReNAgade in 2021 following a sponsored research agreement in the lab of Dr. Flynn. The mission is to explore the potential of novel glycobiology therapies following the pioneering work at Stanford University by Drs. Flynn and Bertozzi on glycoRNA. The GanNA Bio Scientific Advisory Board included Drs. Bertozzi, Cummings, Flynn, and ReNAgade CSO, Pete Smith.
University Conflict of Interest Disclosure
Drs. Bertozzi, Cummings and Flynn consult for ReNAgade Therapeutics.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240426251202/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Lenovo Announces Global Partnership With David Beckham31.3.2026 07:00:00 CEST | Press release
Lenovo today announced a global partnership with David Beckham, bringing together one of the world’s most recognized cultural figures and one of the world’s leading technology companies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330443523/en/ Lenovo Announces Global Partnership With David Beckham The collaboration builds on Lenovo’s expanding role in global football, including its position as the Official Technology Partner of FIFA World Cup 2026™ and the FIFA Women’s World Cup 2027™. This first of its kind Lenovo partnership will see David Beckham participating in Lenovo’s work on sports-focused AI-driven solutions that are transforming the game for clubs, players, officials, and fans, specifically related to improving performance for teams, creating better experiences for fans, enabling more efficient operations, and driving new revenue streams through AI-driven innovation. As someone who runs his own businesses, D
Union of Kansai Governments: Kansai Deep Tech Ecosystem Gains Global Visibility31.3.2026 02:00:00 CEST | Press release
Platform Update Reflects 20-Place Rise in GSER Ranking The Union of Kansai Governments has refreshed the Kansai Startup Ecosystem portal, strengthening the region’s global communication platform for startups and deep tech. At the same time, the “DeepTech Frontier Kansai” website has also been updated, further enhancing international visibility for Kansai’s rapidly growing deep tech ecosystem. Kansai’s startup ecosystem has demonstrated steady growth in recent years. The ecosystem’s total value expanded from USD 2.68 billion in 2023 to USD 3.23 billion in 2025. In addition, Kansai rose 20 places in the Global Startup Ecosystem Ranking (GSER) published by Startup Genome, climbing from 99th in 2023 to 79th in 2025, and early-stage funding reached USD 124 million. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330459051/en/ Kansai’s Strength in Deep Tech Kansai represents a rare ecosystem where fundamental research and indust
Merz Aesthetics® Announces EU Approval of Two New Indications for Their Hyaluronic Acid Filler BELOTERO® Balance30.3.2026 22:49:00 CEST | Press release
Merz Aesthetics®, the world’s largest dedicated medical aesthetics business, is pleased to announce that BELOTERO® Balance has received EU approval for two additional indications: the treatment of infraorbital hollow (including the tear trough) and horizontal forehead lines1*. “With these new approvals, BELOTERO® Balance further strengthens its position as a versatile hyaluronic acid dermal filler, with a wide range of approved facial indications1 designed to integrate seamlessly within the skin and deliver predictable, harmonious aesthetic outcomes,” said Dr. Kerstin Olsson, Head of Medical Affairs EMEA. The approval of these two new indications is supported by compelling clinical evidence: In a clinical investigation on infraorbital hollow, 98.9% of subjects demonstrated visible improvement at Week 8, with long-lasting results sustained up to 72 weeks, and no treatment related serious adverse events reported.2 Similarly, in a postmarket investigation on horizontal forehead lines, 82.
Klarna Payments Now Available at B-Parts, Europe's Largest Automotive Parts Website30.3.2026 21:51:00 CEST | Press release
B-Parts is now offering its customers a more personalised and flexible shopping experience, with interest-free payments via "Pay in 3", amongst other Klarna features. Klarna, the global digital bank and flexible payments provider, is joining forces with B-Parts, a leading online retailer of used and original car parts, to offer consumers greater flexibility, convenience, choice and control at the point of payments, with no interest or hidden fees. Through Klarna’s interest-free installment payments, B-Parts customers will benefit from greater flexibility and control over their finances. Klarna also ensures a secure shopping experience thanks to its buyer protection scheme, as well as a range of features such as cashback and deals. "We continue to grow locally, with an increasing number of brands across different sectors recognising the enormous advantage of offering their customers more payment options, those that make for a more convenient and seamless checkout experience," explains I
Office of His Highness Sheikh Hamdan Bin Ahmed Al Maktoum Holdings & Gatbits IT Infrastructure Announce Launch of GTBS Digital Ecosystem; Mainnet Set for April 202630.3.2026 20:30:00 CEST | Press release
The Office of His Highness Sheikh Hamdan Bin Ahmed Al Maktoum Holdings, in collaboration with Gatbits IT Infrastructure, has officially announced the launch of the GTBS Digital Ecosystem, marking a significant step forward in the global Web3 space. The announcement follows the successful launch of the native GTBS Coin on December 25, with the ecosystem’s mainnet scheduled to go live in April 2026. GTBS represents a full-stack Web3 ecosystem integrating blockchain, artificial intelligence, decentralized finance (DeFi), entertainment, gaming, media, and cloud infrastructure into a unified platform. Built on the philosophy of “All Commitment On Time,” the ecosystem focuses on delivering reliability, scalability, and real-world utility. Designed as a comprehensive digital infrastructure, GTBS goes beyond standalone crypto platforms by offering an integrated environment for users, developers, creators, and enterprises. Its proprietary Layer-1 blockchain powers seamless interaction across se
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom